MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561754 | Name: MS21570
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MS21570 is a GPR171 antagonist that reduces anxiety-like behavior and fear conditioning in mice.

Chemical Structure

MS21570
MS21570
CAS#65373-29-7

Theoretical Analysis

MedKoo Cat#: 561754

Name: MS21570

CAS#: 65373-29-7

Chemical Formula: C10H11N3S2

Exact Mass: 237.0394

Molecular Weight: 237.34

Elemental Analysis: C, 50.61; H, 4.67; N, 17.71; S, 27.02

Price and Availability

Size Price Availability Quantity
10mg USD 250.00 2 Weeks
50mg USD 470.00 2 Weeks
100mg USD 730.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MS21570; MS-21570; MS 21570;
IUPAC/Chemical Name
5-(benzylthio)-N-methyl-1,3,4-thiadiazol-2-amine
InChi Key
KFLNRVSOQJTXDG-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H11N3S2/c1-11-9-12-13-10(15-9)14-7-8-5-3-2-4-6-8/h2-6H,7H2,1H3,(H,11,12)
SMILES Code
CNC(S1)=NN=C1SCC2=CC=CC=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
MS21570 is a selective GPR171 antagonist, with an IC50 of 220 nM.
In vitro activity:
Displacement binding assays show that MS0021570_1 dose dependently and completely displaced radiolabeled BigLEN binding to hypothalamic membranes albeit with a lower affinity (~31-fold) compared to BigLEN (Figure 1c); MS0015917 only partially (~37%) displaced radiolabeled BigLEN binding (Figure 1c). Reference: Reference: Neuropsychopharmacology. 2017 Dec;42(13):2527-2536. https://pubmed.ncbi.nlm.nih.gov/28425495/
In vivo activity:
The role of GPR171 in anxiety-like behavior or fear conditioning was evaluated following systemic or intra-BLA administration of MS0021570_1, as well as following lentiviral-mediated knockdown of GPR171 in the BLA. This study finds that systemic administration of MS0021570_1 attenuates anxiety-like behavior in mice while intra-BLA administration or knockdown of GPR171 in the BLA reduces anxiety-like behavior and fear conditioning. Reference: Neuropsychopharmacology. 2017 Dec;42(13):2527-2536. https://pubmed.ncbi.nlm.nih.gov/28425495/
Solvent mg/mL mM
Solubility
DMSO 74.4 313.33
Ethanol 23.7 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 237.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
Bobeck EN, Gomes I, Pena D, Cummings KA, Clem RL, Mezei M, Devi LA. The BigLEN-GPR171 Peptide Receptor System Within the Basolateral Amygdala Regulates Anxiety-Like Behavior and Contextual Fear Conditioning. Neuropsychopharmacology. 2017 Dec;42(13):2527-2536. doi: 10.1038/npp.2017.79. Epub 2017 Apr 20. PMID: 28425495; PMCID: PMC5686498.
In vitro protocol:
Bobeck EN, Gomes I, Pena D, Cummings KA, Clem RL, Mezei M, Devi LA. The BigLEN-GPR171 Peptide Receptor System Within the Basolateral Amygdala Regulates Anxiety-Like Behavior and Contextual Fear Conditioning. Neuropsychopharmacology. 2017 Dec;42(13):2527-2536. doi: 10.1038/npp.2017.79. Epub 2017 Apr 20. PMID: 28425495; PMCID: PMC5686498.
In vivo protocol:
Bobeck EN, Gomes I, Pena D, Cummings KA, Clem RL, Mezei M, Devi LA. The BigLEN-GPR171 Peptide Receptor System Within the Basolateral Amygdala Regulates Anxiety-Like Behavior and Contextual Fear Conditioning. Neuropsychopharmacology. 2017 Dec;42(13):2527-2536. doi: 10.1038/npp.2017.79. Epub 2017 Apr 20. PMID: 28425495; PMCID: PMC5686498.